The Cardiomyopathy Collective

Shared purpose.
Collective action.

Industry leaders advancing precision diagnosis and care in cardiomyopathy, together.

Inspired, as always, by patients and their families.

Join the Collective

Our Mission

Precision diagnosis.
Actionable answers.

To make diagnosis more precise and actionable for patients, families, and clinicians. Because precision leads to action, and action can make all the difference.

The information to improve cardiomyopathy care already exists. Our work is putting it into the hands of those who need it most.

1.1%

of eligible cardiomyopathy patients receive genetic testing

Bui et al., J Card Fail, 2026

Patients are hidden in plain sight

Right now, people with cardiomyopathy are sitting in heart failure clinics with a one-size-fits-all diagnosis. They are not rare. They are undiagnosed.

Guidelines Exist

ACC, AHA, HRS, HFSA, and ESC all recommend comprehensive diagnostic evaluation, including genetic testing.

Implementation Lags

Despite clear recommendations, genetic testing rates remain below 2% nationally.

Families at Risk

Without diagnosis, affected family members go unidentified. Inherited disease requires family-centered care.

From heart failure to precision care

Cardiomyopathy care is not one test. It is a journey from recognition to diagnosis to treatment. Each step matters.

01

Recognize

Cardiomyopathy hides in unexplained heart failure, arrhythmias, and family histories no one asked about. Recognition starts with knowing when to look.

02

Test

Diagnosis is not one test. It is imaging, phenotyping, family history, and genetics working together. The goal is a precise, actionable diagnosis.

03

Act

A diagnosis only matters if it changes care. Precision diagnosis enables the right therapy, monitoring, and support for the whole family.

We have done this before

ATTR-CM was once considered a rare disease. Prevalence estimates suggested fewer than 1 in 100,000 people were affected.

Then the field started looking. Education campaigns launched. Diagnostic pathways were built. Testing became accessible.

Today, up to 150,000 people in the U.S. are believed to have ATTR-CM. The biology did not change. Diagnosis did.

"The patients were always there. The field just wasn't looking."

ATTR-CM Prevalence Estimates
0.5per 100,000

Before 2019

15-45per 100,000

Today

Better together

No single company can close the diagnostic gap alone. The Cardiomyopathy Collective brings together organizations who share a commitment to finding these patients and changing how cardiomyopathy is diagnosed and treated.

Shared Mission

We work on field-level challenges that benefit all patients, not company-specific agendas.

Shared Governance

Priorities and projects are shaped by members together.

Education

Coordinated efforts to help clinicians recognize cardiomyopathy and understand when to test.

Infrastructure

Building pathways that make guideline-based diagnosis accessible for every patient.

Lead the way with us

We are forming the Cardiomyopathy Collective now and inviting organizations who want to be part of changing how this disease is recognized, diagnosed, and treated.

Virtual Kickoff

Wednesday, March 12, 2025

12:00 PM to 1:00 PM ET

In Person at ACC

Late March 2025

Informal meetup, details to follow

Get in Touch

Collective Partners

Partner Logo
Partner Logo
Your Logo Here
Your Logo Here
Your Logo Here
Your Logo Here
Partner Logo
Partner Logo
Your Logo Here
Your Logo Here
Your Logo Here
Your Logo Here

References

  1. Bui QM, Morales A, Adler ED, et al. Real World Genetic Testing Practices in Cardiomyopathy. J Card Fail. 2026.
  2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022.
  3. Porcari A, Fontana M, Gillmore JD. Transthyretin Cardiac Amyloidosis. Cardiovasc Res. 2023.
  4. Ruberg FL, Maurer MS. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. JAMA. 2024.